Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-crystallin A chain is one of the two major subunits (the other being alpha-crystallin B chain) forming the alpha-crystallin oligomer, which is a member of the small heat shock protein family and the major protein of the vertebrate lens[7][2][4]. It functions both as a structural protein contributing to lens transparency and as a molecular chaperone that binds to misfolded proteins, preventing their aggregation and thus protecting cells from stress-induced damage[2][7][4]. In addition to its primary structural and chaperone functions in the lens, Alpha-crystallin A chain is expressed in other tissues where it plays roles in cellular protection against apoptosis and in the response to physiological stresses. Mutations or deficiencies in this protein are associated with cataracts and a variety of myopathies, while associations with neurodegenerative diseases and cancer have also been observed[1][2][4]. It is not typical as a drug target (such as a receptor or enzyme), but its dysfunction is relevant in disease contexts.
Chaperone-like action: binds to misfolded or partially denatured proteins preventing their aggregation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-crystallin A chain (CRYAA).